RxDoctor Payments Data

Pascual Mendoza, MD

General Practice · San Antonio, TXNPI 1811993850

Payments from drug & device makers

$3,501in general payments, 2019–2025

Across 155 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$821
  • Lilly USA, LLC$372
  • Sanofi-aventis U.S. LLC$372
  • Novo Nordisk$349
  • E.r. Squibb & Sons, L.L.C.$331
  • Boehringer Ingelheim$226
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,485100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,501 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$14,256
Medicare patients
54
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin228$336,379
EliquisApixaban116$129,264
JanuviaSitagliptin Phosphate91$128,734
OzempicSemaglutide65$86,869
FarxigaDapagliflozin Propanediol59$74,209
TrulicityDulaglutide50$72,881
MounjaroTirzepatide56$64,054
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$46,640
MyrbetriqMirabegron36$34,169
TradjentaLinagliptin24$29,594
Bydureon BciseExenatide Microspheres11$27,645
JanumetSitagliptin Phos/Metformin Hcl17$25,618
LinzessLinaclotide27$22,409
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$12,993
Atorvastatin Calcium1,129$9,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$226$365,973252 claims
MerckJanuvia, Janumet$125$154,352108 claims
Lilly USA, LLCTrulicity, Mounjaro$372$136,935106 claims
PfizerEliquis$120$129,264116 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$821$90,810100 claims
Novo NordiskOzempic$349$86,86965 claims
AbbVieLinzess$125$22,40927 claims
Sanofi-aventis U.S. LLCLantus$372$4,86315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,074 general practice providers in Texas.

Other general practice in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →